Report
Patrik Ling
EUR 95.03 For Business Accounts Only

Targovax (Buy, TP: NOK17.00) - Strong OS in mesothelioma

In our view, the updated survival data from the ongoing trial in mesothelioma published this morning gives a good indication of efficacy even though the trial is limited in size. For first-line patients, mOS was at least 18.2 months and for the control arm mOS was a maximum of 14.2 months. We believe Targovax might have to make some changes to the design of the upcoming phase II trial to include the new data from ipilimumab and nivolumab (ipi+nivo) in mesothelioma patients, which could delay its start. Overall, we expect a positive share price reaction to today’s news, and we reiterate our BUY and NOK17 target price.
Underlying
Targovax AS

Targovax ASA is a Norway-based company active within the healthcare sector. The Company is developing two complementary and targeted approaches in immuno-oncology: a peptide-based immunotherapy platform for patients with RAS-mutated cancers and a virus-based immunotherapy platform based on engineered oncolytic viruses armed with potent immune-stimulating transgenes for patients with solid tumors. The Company's candidate, TG01, is a peptide vaccine that targets mutations in the RAS genes that are associated with cancer, and it is in a phase II clinical trial in pancreatic cancer. The Company's other RAS targeting immunotherapy, TG02 is developed for colorectal cancer treatment. The Company's adenoviral candidate, ONCOS-102 is developed for the treatment of solid tumors, such as melanoma as well as ovarian and prostate cancer.

Provider
DnB Markets
DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

 

Analysts
Patrik Ling

Other Reports on these Companies
Other Reports from DnB Markets

ResearchPool Subscriptions

Get the most out of your insights

Get in touch